Is Coumadin affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C9, CYP4F2, VKORC1

Used for: Preventing blood clots in patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism, or mechanical heart valves

Warfarin (sold as Coumadin or Jantoven) has been the classic example of pharmacogenetic variability for decades. Two genes account for most of the person-to-person variation in the right warfarin dose: CYP2C9, which clears the drug out of your system, and VKORC1, which is the drug's target. Together, CYP2C9 and VKORC1 genotypes explain more than half of the variation in stable warfarin dose between individuals, which is why two patients with the same weight, age, and diagnosis can have weekly warfarin doses that differ by 4x or more. Getting this dose right matters: too low and clots form, too high and bleeding becomes life-threatening. That's why warfarin clinics spend enormous effort on INR monitoring, and why pharmacogenetic dosing algorithms for warfarin are among the best-validated in all of medicine.

What's in Coumadin

warfarin affected by CYP2C9, CYP4F2, VKORC1

Affected by CYP2C9, CYP4F2, VKORC1 · CPIC, FDA · Strong evidence

Warfarin is cleared by CYP2C9, and variants that reduce CYP2C9 activity mean the drug accumulates at standard doses. Warfarin works by blocking VKORC1, the enzyme that recycles vitamin K in your liver, so VKORC1 genotype determines how much warfarin you need to achieve that blockade. The combination matters more than either gene alone: a patient with reduced CYP2C9 activity and a sensitive VKORC1 genotype may need as little as 1 mg daily, while a patient with fully active CYP2C9 and a resistant VKORC1 genotype may need 15 mg daily to hit the same INR.

Read the full warfarin genetics guide →

Warfarin phenotype recommendations

Published guidance from CPIC and FDA on how warfarin should be dosed or substituted based on your CYP2C9, VKORC1, CYP4F2 phenotype.

Phenotype	What it means	Recommendation	Evidence
Normal Metabolizer CYP2C9	Your body breaks down warfarin at a normal rate, so the standard dose of this blood thinner should work as expected for you.	CPIC + FDA Following clinical dosing guidelines for starting dose	Strong
Intermediate Metabolizer CYP2C9	Your body breaks down warfarin more slowly than normal, which means the drug stays active in your system longer. You may need a lower dose to avoid an increased risk of bleeding.	CPIC + FDA Follow pharmacogenomic dosing guidelines for optimal starting dose	Strong
Poor Metabolizer CYP2C9	Your body breaks down warfarin much more slowly than normal, causing the drug to build up to higher levels. You will likely need a significantly lower dose to reduce the risk of bleeding complications.	CPIC + FDA Follow pharmacogenomic dosing guidelines for optimal starting dose	Strong
Indeterminate CYP2C9	The impact of your genotype on response to this drug is unknown	CPIC + FDA Following clinical dosing guidelines for starting dose	—
Not available CYP2C9	The impact of your genotype on response to this drug is unknown	CPIC + FDA Following clinical dosing guidelines for starting dose	—
Normal Metabolizer CYP4F2	Your body processes vitamin K at a normal rate, so warfarin should work as expected at the standard dose.	CPIC + FDA Following clinical dosing guidelines for starting dose	Moderate
Intermediate Metabolizer CYP4F2	Your body breaks down vitamin K more slowly, which means warfarin may be less effective at the standard dose. You may need a slightly higher dose for the blood thinner to work properly.	CPIC + FDA Follow pharmacogenomic dosing guidelines for optimal starting dose	Moderate
Indeterminate CYP4F2	The impact of your genotype on response to this drug is unknown	CPIC + FDA Following clinical dosing guidelines for starting dose	—
Not available CYP4F2	The impact of your genotype on response to this drug is unknown	CPIC + FDA Following clinical dosing guidelines for starting dose	—
Normal expression VKORC1	Your body has a normal response to warfarin based on this gene, so the standard dose should provide the expected blood-thinning effect.	CPIC + FDA Following clinical dosing guidelines for starting dose	Strong
Decreased expression VKORC1	Your body is more sensitive to warfarin based on this gene, which means a lower dose is needed to achieve the right blood-thinning effect. Taking the standard dose could increase your risk of bleeding.	CPIC + FDA Follow pharmacogenomic dosing guidelines for optimal starting dose	Strong
Low expression VKORC1	The impact of your genotype on response to this drug is unknown	CPIC + FDA Initiate therapy with recommended starting dose.	—

Sources: CPIC, FDA

The genes behind the guidance

CYP2C9 Cytochrome P450 2C9

CYP2C9 metabolizes warfarin, phenytoin, celecoxib, and some NSAIDs. Variants that reduce its activity are most consequential for warfarin, where even small changes in drug clearance translate into very different doses (and a real bleeding risk if missed).

Poor metabolizers need substantially lower warfarin doses to hit the same INR target.

See all drugs affected by CYP2C9 →

VKORC1 Vitamin K Epoxide Reductase Complex Subunit 1

VKORC1 is warfarin's molecular target. A common promoter variant determines how much VKORC1 your liver produces, and therefore how much warfarin it takes to block the vitamin K cycle enough to thin your blood.

The combination of your VKORC1 and CYP2C9 genotypes explains more than half of the variation in warfarin dose between individuals.

See all drugs affected by VKORC1 →

What this means for you

If you're starting warfarin and your clinician has the option of genotype-guided dosing, take it. The alternative is the traditional approach of starting at 5 mg and adjusting based on weekly INR results, which works but takes weeks to stabilize and carries real bleeding risk during that stabilization period. If you're already stable on warfarin after months or years, your current dose is essentially a functional readout of your combined genotype; knowing the underlying genetic pattern won't change anything. If you've had repeated episodes of over- or under-anticoagulation despite careful monitoring, your CYP2C9 or VKORC1 genotype is worth investigating.

FAQ

Is warfarin still prescribed much given that apixaban and rivaroxaban exist?

Yes. For patients with mechanical heart valves, warfarin remains the standard of care because the direct oral anticoagulants (DOACs) don't have equivalent evidence for that indication. Warfarin is also sometimes preferred for patients with severely reduced kidney function, and it's much less expensive than DOACs, which matters for patients without good drug coverage.

Why do vitamin K and leafy greens matter with warfarin?

Warfarin blocks the vitamin K recycling enzyme (VKORC1), so eating large amounts of vitamin K-rich foods (kale, spinach, broccoli) essentially gives your body more raw material to overcome the block. That interaction is dietary, not pharmacogenetic, but the two interact: a VKORC1 variant that's already resistant to warfarin plus a diet rich in leafy greens can make achieving target INR nearly impossible.

How long does it take for warfarin genetics to affect dose?

Every day you're on warfarin. The pharmacogenetic effect isn't a sudden event; it's the reason your stable maintenance dose is what it is. The highest-risk period is the first 2 to 3 weeks of starting warfarin, when your INR is still being adjusted and a high-sensitivity genotype can cause over-anticoagulation before the clinical team realizes your sensitivity is unusual.

Find out how your genetics affect Coumadin

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.